<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895817</url>
  </required_header>
  <id_info>
    <org_study_id>08-14045</org_study_id>
    <nct_id>NCT00895817</nct_id>
  </id_info>
  <brief_title>Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis</brief_title>
  <official_title>Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical efficacy of proton pump inhibitors in
      comparison to aerosolized swallowed steroids for the treatment of eosinophilic esophagitis
      (EE). EE is an increasingly recognized disorder that has been associated with dysphagia and
      food impaction. The presence of anatomical abnormalities in the esophagus such as
      longitudinal furrows, corrugated rings and a narrow caliber esophagus with friable mucosa are
      classic endoscopic findings. Diagnosis is established with the histologic finding of large
      numbers (&gt; 15) of eosinophils per high power field. The underlying pathologic mechanism
      remains poorly understood but food allergies and aeroallergens have been implicated. It is
      well known that gastroesophageal reflux disease (GERD) may cause esophageal eosinophilia, but
      it is unclear whether a complex relationship exists between GERD and EE, as recent data
      suggests. Furthermore, a large number of patients with clinical presentations and endoscopic
      findings highly suggestive of EE which is confirmed on histology are responding favorably to
      proton pump inhibitors.

      The aims of the study are to (1) compare the clinical efficacy of aerosolized swallowed
      Fluticasone to Esomeprazole for the treatment of eosinophilic esophagitis, (2) determine
      whether proton pump inhibitors are effective in the treatment of eosinophilic esophagitis,
      (3) determine the number of patients with eosinophilic esophagitis that have coexisting
      gastroesophageal reflux disease, and (4) correlate change in eosinophil count to improvement
      in symptoms before and after therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Responded</measure>
    <time_frame>8 weeks</time_frame>
    <description>Histologic resolution of esophageal eosinophilia. Response is defined as achieving &lt; 7 eosinophils/high power field in both the proximal and distal esophagus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Using a validated questionnaire, symptoms will be assessed at baseline and following therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Change</measure>
    <time_frame>8 weeks</time_frame>
    <description>Following therapy, resolution of EE findings will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Swallowed fluticasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Swallowed fluticasone</intervention_name>
    <description>440 µg twice daily for 8 weeks</description>
    <arm_group_label>Swallowed fluticasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>40 mg once daily for 8 weeks</description>
    <arm_group_label>Esomeprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an established diagnosis of EE defined as &gt; 20 eosinophils/HPF in the
             setting of dysphagia or food impaction.

          -  Males and females age &gt; 18 years of age.

          -  Ability to undergo ambulatory pH monitoring.

          -  DEERS (Defense Enrollment Eligibility Reporting System) eligible.

          -  Willingness to take a one month holiday from a PPI or steroids if they have been
             prescribed this prior to enrollment.

          -  Willingness to participate and have additional biopsies taken during endoscopy and
             answer a questionnaire.

        Exclusion Criteria:

          -  Patients &lt; 18 years of age.

          -  Inability to give consent.

          -  Inability to undergo endoscopy or contraindications to endoscopy. Any medical
             condition or disorder (including drug allergies), which would preclude the use of
             conscious sedation or the ability to tolerate upper endoscopy.

          -  Contraindications to proton pump inhibitors or steroids.

          -  Inability to accurately fill out a short questionnaire.

          -  Pregnant females. A urine beta human chorionic gonadotropin (BHCG) prior to endoscopy
             will be offered to all female patients of child bearing potential (exceptions include
             post-menopausal, hysterectomy or bilateral tubal ligation). Positive BHCG results will
             prevent enrollment.

          -  Known coagulation abnormalities, thrombocytopenia and patients on coumadin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fouad J Moawad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2009</study_first_submitted>
  <study_first_submitted_qc>May 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <results_first_submitted>December 28, 2012</results_first_submitted>
  <results_first_submitted_qc>March 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2013</results_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Walter Reed Army Medical Center</investigator_affiliation>
    <investigator_full_name>Fouad J. Moawad</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Eosinophilic esophagitis</keyword>
  <keyword>acid reflux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects with symptoms of esophageal dysfunction were recruited from the GI clinic of Walter Reed Army Medical Center. Recruitment dates were from 2008-2010.</recruitment_details>
      <pre_assignment_details>Subjects with a confirmed diagnosis of EE based on symptoms and tissue biopsies were offered enrollment.All subject underwent 24-hour pH studies to stratify GERD positive and GERD negative. A computer generated list of random numbers was then used to separate patients into two equal treatment groups (esomeprazole and fluticasone proprionate).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Esomeprazole</title>
          <description>Esomeprazole : 40 mg once daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Swallowed Fluticasone</title>
          <description>Swallowed fluticasone : 440 µg twice daily for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Esomeprazole</title>
          <description>Esomeprazole : 40 mg once daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Swallowed Fluticasone</title>
          <description>Swallowed fluticasone : 440 µg twice daily for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="10"/>
                    <measurement group_id="B2" value="38" spread="10"/>
                    <measurement group_id="B3" value="38" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Responded</title>
        <description>Histologic resolution of esophageal eosinophilia. Response is defined as achieving &lt; 7 eosinophils/high power field in both the proximal and distal esophagus.</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample size estimation was based on the assumptions:10% of the EE patients will respond to PPI compared to 55% of patients treated with steroids. Controlling the probability of a Type I error at alpha=0.05, a sample of 38 patients in the treatment groups (19 in each arm) will have 80% power to detect a difference in treatment response of 45%.</population>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole : 40 mg once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Swallowed Fluticasone</title>
            <description>Swallowed fluticasone : 440 µg twice daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Responded</title>
          <description>Histologic resolution of esophageal eosinophilia. Response is defined as achieving &lt; 7 eosinophils/high power field in both the proximal and distal esophagus.</description>
          <population>Sample size estimation was based on the assumptions:10% of the EE patients will respond to PPI compared to 55% of patients treated with steroids. Controlling the probability of a Type I error at alpha=0.05, a sample of 38 patients in the treatment groups (19 in each arm) will have 80% power to detect a difference in treatment response of 45%.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Score</title>
        <description>Using a validated questionnaire, symptoms will be assessed at baseline and following therapy.</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopic Change</title>
        <description>Following therapy, resolution of EE findings will be assessed.</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Esomeprazole</title>
          <description>Esomeprazole : 40 mg once daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Swallowed Fluticasone</title>
          <description>Swallowed fluticasone : 440 µg twice daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fouad J Moawad</name_or_title>
      <organization>Walter Reed Army Medical Center</organization>
      <phone>(301) 295-4600</phone>
      <email>fouad.moawad@us.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

